Last updated on July 2018

Type 2 Diabetes Mellitus with Heart Disease


Brief description of study

Type 2 Diabetes Mellitus with Heart Disease

Detailed Study Description

"THE VERTIS CV STUDY" Type 2 Diabetes Mellitus and Established Vascular Disease

Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes http://www.mercknewsroom.com/news-release/corporate-news/merck-and-pfizer-announce-two-pivotal-phase-3-studies-ertugliflozin-inve

 

Clinical Study Identifier: TX144439

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )